Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Trade
- Science and Technology
- Taxation and Finance
Subject Matter Details
Policies or Program
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
- Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
- Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
- Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
- The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
Policies or Program, Regulation
- Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Regulation
- Amendments to the Patented Medicines Regulations published in Canada Gazette, Part II on August 21, 2019 and June 10, 2020.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
20 Bay Street
Suite 1520
Toronto, ON M5J 2N8
Canada
Telephone number:
647-790-1602
Web address:
www.vrtx.com
Client representative
Christina Cunningham, Director of Public Affairs - Canada
Parent Company Information
- Vertex Pharmaceuticals Incorporated
-
50 Northern Ave
Boston, MA 02210
United States of America
Coalition Members Information
Vertex Pharmaceuticals (Canada) Inc. is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Vertex Pharmaceuticals (Canada) Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Vertex Pharmaceuticals (Canada) Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
WILLIAM DEMPSTER
|
Public offices held
Business address:
150 Metcalfe Street
Suite 604
OTTAWA, ON K2P 1P1
Canada
Telephone number:
613-614-0283
Fax number:
613-249-3645
Consultant Firm and Address
Firm:
3Sixty Public Affairs Inc. / 3Sixty Public Affairs Inc.
Address:
150 Metcalfe Street
Suite 604
Ottawa, ON K2P 1P1
Canada
Telephone number:
613-800-8340
Fax number:
613-800-8343